Tonix Pharm Holdings (TNXP) Stock Price, Quote & News

Company Profile

Tonix Pharmaceuticals Holding Corp. operates as a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of unmet medical needs and focuses on developing and commercializing therapeutics to treat and prevent human disease. The company's flagship product, TONMYA (cyclobenzaprine HCl sublingual tablets 2.8 mg), therapy is used for the treatment of fibromyalgia. It markets Zembrace SymTouch and Tosymra for the treatment o...

Industry: Biotechnology

Sector: Healthcare

Phone: 862 799 8599

Fax: 862 904 8163

Website: www.tonixpharma.com

Address:

26 Main Street, Suite 101, Chatham, United States

HubAllianceModern Mar. 22 at 4:38 AM

$TNXP biotech, just watching.

0 · Reply

TheUnmaker Mar. 22 at 12:05 AM

$TNXP https://www.stocktitan.net/news/TNXP/tonix-pharmaceuticals-to-present-at-bio-europe-spring-i4ejecx79iqs.html

0 · Reply

TheUnmaker Mar. 21 at 11:39 PM

$TNXP https://www.fibromyalgiafund.org/tonmya-novel-fibromyalgia-treatment-but-will-it-deliver/

0 · Reply

TheUnmaker Mar. 21 at 10:54 PM

$TNXP Know what you own. As a shareholder youre an owner of a Nasdaq Global Select Market stock. https://www.investopedia.com/terms/n/nqgs.asp https://www.investopedia.com/terms/n/nqgs.asp

0 · Reply

TheUnmaker Mar. 21 at 8:47 PM

$TNXP old news but 5 year contract 34 million dollars with DOD sounds bullish to me. https://ir.tonixpharma.com/news-events/press-releases/detail/1491/tonix-pharmaceuticals-awarded-up-to-34-million-u-s

0 · Reply

dachshund36 Mar. 21 at 8:44 PM

$TNXP Modeling this four weeks forward with linear and exponential models. Which do you like better? (I can make the R script available if anyone is interested.)

1 · Reply

TheUnmaker Mar. 21 at 8:43 PM

$TNXP TNXP common stock is listed on the Nasdaq Global Select Market (as of March 3, 2026), having moved up from the Nasdaq Capital Market.

2 · Reply

flacidStonks Mar. 21 at 8:08 PM

$TNXP

0 · Reply

flacidStonks Mar. 21 at 7:49 PM

$TNXP loaded with 19k shares for Monday.

0 · Reply

JuggernautRaider Mar. 21 at 7:43 PM

$TNXP found a few new bears to block. Ignore the noise and shorts 🚀

0 · Reply

Tonix Pharmaceuticals to Present at BIO-Europe Spring 2026

Mar 17, 2026, 4:35 PM EDT - 4 days ago

Tonix Pharmaceuticals Announces Oral Presentation and Two Poster Presentations on Preclinical Immuno-oncology Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026

Mar 17, 2026, 10:00 AM EDT - 4 days ago

Tonix Q4: Revenue Beat, EPS Miss, Early Signs Of Tonmya Momentum

Mar 13, 2026, 7:10 AM EDT - 8 days ago

Tonix Pharmaceuticals Says Prescriptions For Chronic Pain Drug Top 4,200 Since Launch

Mar 12, 2026, 5:30 PM EDT - 9 days ago

Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Mar 10, 2026, 8:00 AM EDT - 11 days ago

Tonix Pharmaceuticals Presented Post Hoc Analyses of Phase 3 Data on TONMYATM at the 8th International Congress on Controversies in Fibromyalgia

Mar 9, 2026, 4:30 PM EDT - 12 days ago

Tonix Pharmaceuticals Presented Data on TONMYA™ in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting

Mar 9, 2026, 4:30 PM EDT - 12 days ago

Tonix Pharmaceuticals Presented Data on TONMYATM in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting

Mar 5, 2026, 4:15 PM EST - 16 days ago

Tonix Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Studies of TONMYA™ and Prototype Formulations in the Journal Clinical Pharmacology in Drug Development

Mar 3, 2026, 4:30 PM EST - 18 days ago

Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2026 American Academy of Pain Medicine PainConnect Annual Meeting

Mar 3, 2026, 7:04 AM EST - 18 days ago

Tonix Pharmaceuticals Stock Dips After Nasdaq Uplisting

Mar 3, 2026, 6:00 AM EST - 18 days ago

Tonix Pharmaceuticals Announces Uplisting from Nasdaq Capital Market to Nasdaq Global Select Market

Feb 25, 2026, 7:00 AM EST - 24 days ago

Tonix Pharmaceuticals to Participate in Two Investor Conferences in March

Jan 30, 2026, 7:00 AM EST - 7 weeks ago

Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit

Jan 6, 2026, 7:00 AM EST - 2 months ago

Tonix Pharmaceuticals to Present at Two Investor Conferences in January 2026

Dec 29, 2025, 7:57 AM EST - 2 months ago

Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering

Dec 29, 2025, 7:45 AM EST - 2 months ago

Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800)

Dec 16, 2025, 7:00 AM EST - 3 months ago

Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers University

Dec 9, 2025, 7:00 AM EST - 3 months ago

Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel

Nov 24, 2025, 3:35 PM EST - 4 months ago

Tonix: Maintaining Buy Rating With Potential Tonmya Expansion Indications

Nov 24, 2025, 7:00 AM EST - 4 months ago

Tonix Pharmaceuticals Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder

Nov 17, 2025, 7:00 AM EST - 4 months ago

Tonix Pharmaceuticals Announces U.S. Commercial Availability of TONMYA™ (cyclobenzaprine HCl sublingual tablets) as a First-in-Class Fibromyalgia Treatment

Nov 14, 2025, 9:41 AM EST - 4 months ago

Tonix Q3 2025 Earnings Recap And Tonmya Launch Outlook

Nov 10, 2025, 4:15 PM EST - 4 months ago

Tonix Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Highlights

Nov 6, 2025, 7:00 AM EST - 4 months ago

Tonix Pharmaceuticals to Participate in the Stifel 2025 Healthcare Conference

Nov 4, 2025, 7:00 AM EST - 4 months ago

Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Advance Phase 2 Clinical Trial of Dimeric Fc-modified anti-CD40L mAb, TNX-1500, to Prevent Kidney Transplant Organ Rejection

Oct 28, 2025, 7:00 AM EDT - 5 months ago

Tonix Pharmaceuticals Announces Presentation at BIO-Europe 2025

Oct 27, 2025, 7:00 AM EDT - 5 months ago

Tonix Pharmaceuticals Presented Data on Tonmya™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2025 American College of Rheumatology (ACR) Convergence

Oct 22, 2025, 7:00 AM EDT - 5 months ago

Tonix Pharmaceuticals Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix's Intranasal Potentiated Oxytocin in AVP-D Conducted by Massachusetts General Hospital

Oct 21, 2025, 7:00 AM EDT - 5 months ago

Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2025 American College of Rheumatology (ACR) Convergence

Oct 17, 2025, 7:00 AM EDT - 5 months ago

Tonix Pharmaceuticals Presented Data on TNX-801 Mpox Vaccine at World Vaccine Congress–Europe 2025

Oct 14, 2025, 7:00 AM EDT - 5 months ago

Tonix Pharmaceuticals Presented an Update on Fc-modified anti-CD40L mAb, TNX-1500, at the 61st Annual Congress of the Japan Society for Transplantation

Oct 9, 2025, 7:00 AM EDT - 5 months ago

Tonix Pharmaceuticals to Present and Participate in Panel Discussion at World Vaccine Congress, Europe 2025

Sep 30, 2025, 8:30 AM EDT - 6 months ago

Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Ganesh Kamath as Head of Market Access

Sep 29, 2025, 7:00 AM EDT - 6 months ago

Tonix Pharmaceuticals Plans to Initiate Prader-Willi Syndrome Phase 2 Trial of TNX-2900 (Intranasal Potentiated Oxytocin) in 2026

Sep 18, 2025, 8:00 AM EDT - 6 months ago

Tonix Pharmaceuticals Announces Positive Pre-IND Meeting with FDA for TNX-102 SL for the Treatment of Major Depressive Disorder

Sep 17, 2025, 7:00 AM EDT - 6 months ago

Tonix Pharmaceuticals Announces In-licensing Phase 2/3-Ready Monoclonal Antibody Designed for Seasonal Prevention of Lyme Disease (TNX-4800)

Sep 8, 2025, 7:00 AM EDT - 6 months ago

Tonix Pharmaceuticals Presents Clinical Data on Tonmya™ for the Treatment of Fibromyalgia at PAINWEEK 2025

Aug 28, 2025, 7:00 AM EDT - 7 months ago

Tonix Pharmaceuticals to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2025

Aug 19, 2025, 12:28 PM EDT - 7 months ago

Tonix Pharmaceuticals Soars, Then Sinks: What's Next After Tonmya's Approval (Upgrade)

Aug 16, 2025, 8:45 AM EDT - 7 months ago

Tonix Secures Fibromyalgia Approval - What Investors Should Know

Aug 15, 2025, 3:50 PM EDT - 7 months ago

US FDA approves Tonix Pharma's drug to manage pain related to chronic condition

Aug 15, 2025, 3:44 PM EDT - 7 months ago

Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia

Aug 11, 2025, 4:15 PM EDT - 7 months ago

Tonix Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Highlights

Jul 21, 2025, 7:00 AM EDT - 8 months ago

Tonix Pharmaceuticals Announces the Launch of the “Move Fibro Forward” Campaign to Bring Awareness to Individuals Impacted by Fibromyalgia

Jul 10, 2025, 7:00 AM EDT - 9 months ago

Tonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate TNX-801 at the Vaccine Congress 2025

Jul 9, 2025, 4:01 PM EDT - 9 months ago

Tonix Pharmaceuticals Announces On-line Publication of Phase 3 RESILIENT Trial Results of TNX-102 SL for Fibromyalgia in the Peer Reviewed Journal, Pain Medicine

Jul 7, 2025, 7:00 AM EDT - 9 months ago

Tonix Pharmaceuticals Announces Oral Presentation on Mpox and Smallpox vaccine candidate TNX-801 at the Vaccine Congress 2025

Jul 2, 2025, 7:00 AM EDT - 9 months ago

Tonix Pharmaceuticals Announces Peer-Reviewed Publication in Cancer Cell Journal Highlighting Positive Preclinical Data of mTNX-1700 in Gastric Cancer Animal Models

Jun 30, 2025, 7:00 AM EDT - 9 months ago

Tonix Pharmaceuticals Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

HubAllianceModern Mar. 22 at 4:38 AM

$TNXP biotech, just watching.

0 · Reply

TheUnmaker Mar. 22 at 12:05 AM

$TNXP https://www.stocktitan.net/news/TNXP/tonix-pharmaceuticals-to-present-at-bio-europe-spring-i4ejecx79iqs.html

0 · Reply

TheUnmaker Mar. 21 at 11:39 PM

$TNXP https://www.fibromyalgiafund.org/tonmya-novel-fibromyalgia-treatment-but-will-it-deliver/

0 · Reply

TheUnmaker Mar. 21 at 10:54 PM

$TNXP Know what you own. As a shareholder youre an owner of a Nasdaq Global Select Market stock. https://www.investopedia.com/terms/n/nqgs.asp https://www.investopedia.com/terms/n/nqgs.asp

0 · Reply

TheUnmaker Mar. 21 at 8:47 PM

0 · Reply

dachshund36 Mar. 21 at 8:44 PM

$TNXP Modeling this four weeks forward with linear and exponential models. Which do you like better? (I can make the R script available if anyone is interested.)

1 · Reply

TheUnmaker Mar. 21 at 8:43 PM

$TNXP TNXP common stock is listed on the Nasdaq Global Select Market (as of March 3, 2026), having moved up from the Nasdaq Capital Market.

2 · Reply

flacidStonks Mar. 21 at 8:08 PM

$TNXP

0 · Reply

flacidStonks Mar. 21 at 7:49 PM

$TNXP loaded with 19k shares for Monday.

0 · Reply

JuggernautRaider Mar. 21 at 7:43 PM

$TNXP found a few new bears to block. Ignore the noise and shorts 🚀

0 · Reply

Manu56 Mar. 21 at 7:29 PM

$TNXP 🤣🤣🤣🤣 Hugeassss it’s the bin for you my friend you’ve got some company in there 🤭 I’m afraid you’re blocked as well bye-bye 👋 😎

0 · Reply

hofno2003 Mar. 21 at 7:24 PM

$DERM $MIST $TNXP 3 companies, 3 best in class products in early launch phase.

2 · Reply

TheSpaniard_ Mar. 21 at 5:12 PM

$TNXP @hugessssss you have a home insurance most probably, but that does not mean you are intending to have your house burned right? 😉

0 · Reply

Piotrux666 Mar. 21 at 4:49 PM

$TNXP 3/13/2026 TRx 750

3 · Reply

ACMTrader Mar. 21 at 4:21 PM

$TNXP 🚀🚀 may be one of the most mispriced small-cap biotech launches right now. TONMYA = 1st new fibromyalgia drug in 15+ years. Company already reported ~4.2k cumulative scripts, ~2.5k patients started, 1.5k+ prescribers very early post-launch. If Symphony is undercounting and the real gap is 1.5x–1.7x (unofficial theory), market may be massively underestimating demand. Bullish YE26 setup: 2.2k–3.0k weekly TRx $220M–$300M gross annualized run-rate $160M–$230M 2027 net sales potential Bull case: $50–$75/share Blue sky: ~$90 if TONMYA becomes a true commercial winner + dilution fears fade. 🚀💎🚀💎

1 · Reply

hugessssss Mar. 21 at 4:16 PM

$TNXP reverse split again. 1:2 to 1:250. Crazy

1 · Reply

JustAguysOpinion Mar. 21 at 3:20 PM

$TNXP Years they point out tonix had no products. Tonmya is their flagship drug everyone was waiting for and it's doing well. Revenue up, loss down, drug doing a little better than expected and uplisted to a market where primarily large caps are. That itself is bullish AF. We were pushing well to hit next leg up. This is a hail Mary by the shorts. Most those sells I can almost guarantee are theirs. They have a nice. Hunk of share to do their shorting loop. They didn't return bulk what they took out Friday. No one can predict who wins Monday but if bulls do we continue on the road to squeeze town. Small 13m float 2m short this has the setup to be one of the top squeezes of 26. Good luck to all

1 · Reply

PennyINC1 Mar. 21 at 2:31 PM

$TNXP if you're new to this CEO Seth Dilution Show, 5yr chart says it all. Most investors here got played and bagged at $60SP few months back. New investors take heed and leave while you can or be left in Seth's dust like the other folks

1 · Reply

Stino715pro Mar. 21 at 1:28 PM

$TNXP Frankgelbert if you don’t like it here, just go away, the world is - enough 🥵

0 · Reply

FrankGelbert Mar. 21 at 12:57 PM

$TNXP Alleluja! A groth of 61*1.6=97 units per week means, that Tonix will be cash flow positive at Christmas, if this trend continues! Break even is a nice Christmas gift, isn't it? I am hoping for a long period of mispricing. Shorties, lets go! Small investors, sell this stupid company! The next dilution will arrive soon! War times change everything! Biotec is overpriced. Save your money! Seth will dilute again! He likes having a lot of cash. Only cash is no trash nowadays. Look at Warren Buffet and his huge cash pile! He is the best forever! Follow him before it's too late, and Seth is diluting!

1 · Reply

vlentini Mar. 21 at 12:12 PM

$TNXP Non sono un' estimatore di Lederman ma parlare di raggruppamento azioni per un titolo che attualmente vale 15 S è da idioti o stupidi orsi!

0 · Reply

PolloStock Mar. 21 at 12:12 PM

$TNXP number of refills almost doubled from last week, that’s the BIG story this week!

1 · Reply

Market Cap	201.08M
Revenue (ttm)	13.11M
Net Income (ttm)	-124.02M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-946.00%
Debt to Equity Ratio	0.00

Volume	1,042,900
Avg Vol	382,744
Day's Range	N/A - N/A
Shares Out	13.41M
Stochastic %K	48%
Beta	1.88
Analysts	Strong Sell
Price Target	$54.33